Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China

被引:36
作者
Li, Shouwei [2 ,3 ]
Yan, Changxiang [2 ]
Huang, Lei [1 ]
Qiu, Xiaoguang [1 ]
Wang, Zhongcheng [3 ]
Jiang, Tao [1 ,3 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
[2] Capital Med Univ, Beijing Sanbo Brain Hosp, Dept Neurosurg, Beijing 100050, Peoples R China
[3] Beijing Neurosurg Inst, Beijing, Peoples R China
关键词
anaplastic oligodendroglial tumor; IDH1; mutation; LOH 1p and 19q; MGMT; prognostic factor; EUROPEAN ORGANIZATION; CHROMOSOME; 1P; 19Q STATUS; MGMT GENE; CHEMOTHERAPY; TEMOZOLOMIDE; EXPRESSION; SURVIVAL; P53; OLIGOASTROCYTOMAS;
D O I
10.1093/neuonc/nor185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The increased chemosensitivity of oligodendroglial tumors has been associated with loss of heterozygosity (LOH) on chromosomes 1p and 19q. Other clinical and molecular factors have also been identified as being prognostic and predictive for treatment outcome. Seventy-seven patients with anaplastic oligodendroglioma (AO) or anaplastic oligoastrocytoma (AOA), treated in Beijing Tiantan Hospital from 2006 through 2008, were reviewed. LOH 1p, LOH 19q, IDH1 mutation, O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and protein expression level of MGMT, P53, EGFR, and Ki-67 were evaluated. Age at diagnosis, LOH 1p and 19q, IDH1 mutation, P53 expression level, reoperation when progression, and adjuvant chemotherapy were statistically significant factors for overall survival (OS) in univariate analysis. Further multivariate analysis showed that age at diagnosis (P = .010), LOH 1p and 19q (P = .016), IDH1 mutation (P = .011), and reoperation after progression (P = .048) were independent predictors for longer survival in these patients. Nonrandom associations were found between LOH 1p and LOH 19q, MGMT promoter methylation and LOH 1p or 19q, IDH1 mutation and LOH 1p and 19q, IDH1 mutation and MGMT promoter methylation, whereas mutual exclusion was found between MGMT promoter methylation and MGMT expression level. The present study confirmed that age at diagnosis, LOH 1p and 19q, IDH1 mutation, and reoperation after progression were independent significant prognostic factors for patients with anaplastic oligodendroglial tumors. Inter-relationship between LOH 1p, LOH 19q, IDH1 mutation, MGMT promoter methylation, and MGMT expression level were also revealed. Future clinical trials for AO and AOA should consider the molecular alterations of patients.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 29 条
  • [1] Anaplastic oligodendroglioma
    Blakeley, Jaishri
    Grossman, Stuart
    [J]. CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2008, 10 (04) : 295 - 307
  • [2] Oligodendrogliomas: Molecular Biology and Treatment
    Bromberg, Jacolien E. C.
    van den Bent, Martin J.
    [J]. ONCOLOGIST, 2009, 14 (02) : 155 - 163
  • [3] Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
    Cairncross, Gregory
    Berkey, Brian
    Shaw, Edward
    Jenkins, Robert
    Scheithauer, Bernd
    Brachman, David
    Buckner, Jan
    Fink, Karen
    Souhami, Luis
    Laperierre, Normand
    Mehta, Minesh
    Curran, Walter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 2707 - 2714
  • [4] SUCCESSFUL CHEMOTHERAPY FOR RECURRENT MALIGNANT OLIGODENDROGLIOMA
    CAIRNCROSS, JG
    MACDONALD, DR
    [J]. ANNALS OF NEUROLOGY, 1988, 23 (04) : 360 - 364
  • [5] Rapid detection of allelic losses in brain tumours using microsatellite repeat markers and high-performance liquid chromatography
    Chernova, OB
    Barnett, GH
    Cowell, JK
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 (12) : 1889 - 1893
  • [6] Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases
    Dehghani, F
    Schachenmayr, W
    Laun, A
    Korf, HW
    [J]. ACTA NEUROPATHOLOGICA, 1998, 95 (05) : 493 - 504
  • [7] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003
  • [8] Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors
    Huang, L.
    Jiang, T.
    Yuan, F.
    Li, G. L.
    Liu, E. Z.
    Wang, Z. C.
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2008, 110 (10) : 1020 - 1024
  • [9] Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study
    Huang, L.
    Jiang, T.
    Yuan, F.
    Li, G. -L.
    Cui, Y.
    Liu, E. -Z.
    Wang, Z. -C.
    [J]. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2009, 35 (04) : 367 - 379
  • [10] Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors:: A clinicopathological study using fluorescence in situ hybridization
    Jeon, Yoon Kyung
    Park, Kyeongmee
    Park, Chul Ki
    Paek, Sun Ha
    Jung, Hee Won
    Park, Sung-Hye
    [J]. NEUROPATHOLOGY, 2007, 27 (01) : 10 - 20